These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Multiple Myeloma and the Immune Microenvironment. Kawano Y; Roccaro AM; Ghobrial IM; Azzi J Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978 [TBL] [Abstract][Full Text] [Related]
6. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis. Gámez B; Edwards CM Curr Osteoporos Rep; 2018 Dec; 16(6):635-641. PubMed ID: 30229522 [TBL] [Abstract][Full Text] [Related]
7. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells. van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance. Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871 [TBL] [Abstract][Full Text] [Related]
9. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ]. Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009 [TBL] [Abstract][Full Text] [Related]
10. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Dutta AK; Fink JL; Grady JP; Morgan GJ; Mullighan CG; To LB; Hewett DR; Zannettino ACW Leukemia; 2019 Feb; 33(2):457-468. PubMed ID: 30046162 [TBL] [Abstract][Full Text] [Related]
11. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity. Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394 [TBL] [Abstract][Full Text] [Related]
12. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311 [TBL] [Abstract][Full Text] [Related]
13. Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma. Tomasson MH; Ali M; De Oliveira V; Xiao Q; Jethava Y; Zhan F; Fitzsimmons AM; Bates ML Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30453544 [TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma and multiple plasmacytomas associated with free gamma heavy chain, free kappa light chain and IgGk paraproteins: an unusual triple gammopathy. Deighan WI; O'Kane MJ; McNicholl FP; Keren DF Ann Clin Biochem; 2016 Nov; 53(6):706-711. PubMed ID: 27166317 [TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management. Hillengass J; Moehler T; Hundemer M Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683 [TBL] [Abstract][Full Text] [Related]
17. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal Gammopathy of Renal Significance-A Rare Renal Presentation: A Review of Cases Reported. Kichloo A; Nawaz N; Singh J; Aljadah M; Albosta MS; Bhanot R J Investig Med High Impact Case Rep; 2020; 8():2324709620940500. PubMed ID: 32643956 [TBL] [Abstract][Full Text] [Related]
19. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Pisano M; Cheng Y; Sun F; Dhakal B; D'Souza A; Chhabra S; Knight JM; Rao S; Zhan F; Hari P; Janz S Front Immunol; 2021; 12():667054. PubMed ID: 34149703 [TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]